Albireo Receives European Marketing Authorization of Bylvay™ (odevixibat), the First Drug Treatment for Progressive Familial Intrahepatic Cholestasis (PFIC)
EU market potential, with launch planned for September 2021, following price listing.
U.S. FDA has set an action date of July 20, 2021